Yan Yu

11PUBLICATIONS
72CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 22, 2026
RBM10 Deficiency Promotes Anti-PD-1 Resistance in LUAD via STING Alternative Splicing-Driven CCL7 Signaling and Macrophage Polarization.

|Mar 12, 2026
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

Jian-Chun Duan, Jia Zhong, Bo-Yang Sun

|Sep 18, 2025
Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: A retrospective multicentre study.

Mingjun Xu, Yan Xu, Yingchun Man

|Jun 17, 2025
Integrating multi-omics to unveil PSMD12 as a critical gene in promoting brain metastases of lung adenocarcinoma.

Xin Li, Juxuan Zhang, Meng Zhang

|May 16, 2025
Phase I/II Study of Tifcemalimab, an Anti-B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.

Ying Cheng, Jie Wang, Yan Yu

|Feb 27, 2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial.

Dan-Yun Ruan, Wen-Wen Huang, Yongsheng Li

Pageof 2

Frequent Collaborators

2 joint publications

Ying Cheng

2 joint publications

Jie Wang

1 joint publications

Yangchun Gu

1 joint publications

Yan Xu